We are pleased to announce that the United States Patent and Trademark Office (USPTO) has officially granted APTA Therapeutics a US patent 12,630,828 within a pivotal patent family covering the design and medical use of all functional aptamer compounds targeting autoantibodies as well as the use of a novel algorithm to identify elements of structural commonality. Further patents have already been granted and will be granted in the future to generate broad patent protection for this key invention, in the US and worldwide.

APTA Therapeutics is pleased to announce that it has entered into a collaboration with the Fraunhofer Institute for Algorithms and Scientific Computing (SCAI) to implement state-of-the-art data-and knowledge-driven methods to better define patient recruitment for the upcoming clinical trials in post-viral infectious diseases.

Click here for the article:

https://www.tagesspiegel.de/gesundheit/zweite-chance-fur-bc-007-wir-sind-vom-potenzial-fur-eine-wirksame-behandlung-von-long-covid-uberzeugt-15402914.html

(Full article requires a subscription)

Click here for the article:

https://www.riffreporter.de/de/wissen/long-covid-mecfs-bc007-rovunaptabin-klinische-studien-erlangen-apta-berlin-cures
(Full article requires a subscription)

APTA Therapeutics, today announced that it has received notices of allowance for a key patent application in both the United States and Japan, marking a significant milestone in the company’s intellectual property strategy.

APTA Therapeutics is pleased to announce that it has entered into an agreement with Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT) to support an Investigator Initiated Trial with rovunaptabin in patients with long COVID.